
Progressive fibrosing interstitial lung disease Program in Pharmaceutical Benefits Scheme 012-22042647

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of the Pharmaceutical Benefits Scheme
(PBS) subsidised nintedanib for patients with progressive fibrosing
interstitial lung disease (PF-ILD).

Progressive fibrosing interstitial lung disease and listing dates

Progressive fibrosing interstitial lung disease is part of a large group
of lung disorders. It causes progressive scarring (fibrosis) of the lung
tissue.

Listing date is as follows:

-   nintedanib - 1 May 2022

See Written Authority Required Drugs for further information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
items codes, restriction, the Pharmaceutical Benefits Scheme (PBS) and
the Services Australia websites.

Related links

Manage work items in Processing and National Demand Allocation (PaNDA)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA)

Process telephone authority approval application

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
